10x Genomics Inc (NASDAQ:TXG)’s traded shares stood at 2.68 million during the last session, with the company’s beta value hitting 1.83. At the close of trading, the stock’s price was $14.98, to imply a decrease of -2.98% or -$0.46 in intraday trading. The TXG share’s 52-week high remains $51.22, putting it -241.92% down since that peak but still an impressive 13.55% since price per share fell to its 52-week low of $12.95. The company has a valuation of $1.81B, with an average of 1.71 million shares in intraday trading volume over the past 10 days and average of 1.91 million shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for 10x Genomics Inc (TXG), translating to a mean rating of 2.30. Of 8 analyst(s) looking at the stock, 0 analyst(s) give TXG a Sell rating. 0 of those analysts rate the stock as Overweight while 5 advise Hold as 3 recommend it as a Buy.
10x Genomics Inc (NASDAQ:TXG) trade information
After registering a -2.98% downside in the last session, 10x Genomics Inc (TXG) has traded red over the past five days. The 5-day price performance for the stock is -3.54%, and 0.20% over 30 days. With these gigs, the year-to-date price performance is 4.32%. Short interest in 10x Genomics Inc (NASDAQ:TXG) saw shorts transact 6.6 million shares and set a 4.05 days time to cover.
The extremes give us $32 and $46 for target low and target high price respectively. As such, TXG has been trading -207.08% off suggested target high and -113.62% from its likely low.
10x Genomics Inc (TXG) estimates and forecasts
Looking at statistics comparing 10x Genomics Inc share performance against respective industry, we note that the company has underperformed competitors. 10x Genomics Inc (TXG) shares are -25.10% down over the last 6 months, with its year-to-date growth rate lower than industry average at 13.86% against 24.90%.
TXG Dividends
10x Genomics Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
10x Genomics Inc (NASDAQ:TXG)’s Major holders
10x Genomics Inc insiders hold 2.16% of total outstanding shares, with institutional holders owning 97.77% of the shares at 99.93% float percentage. In total, 97.77% institutions holds shares in the company, led by FMR LLC. As of 2024-06-30, the company held over 13.01 million shares (or 10.8971% of shares), all amounting to roughly $253.05 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 10.19 million shares, or about 8.5341% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $198.18 million.
We also have ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the 10x Genomics Inc (TXG) shares. Going by data provided on Nov 30, 2024 , ARK ETF Tr-ARK Innovation ETF holds roughly 8.3 shares. This is just over 7.76% of the total shares, with a market valuation of $124.39 million. Data from the same date shows that the other fund manager holds a little less at 3.25, or 3.04% of the shares, all valued at about 48.65 million.
